Compare Novavax Inc (NVAX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Ryanair Holdings plc — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Ryanair Holdings plc trades at $60.01 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 22.6× Novavax Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RYAAY | |
|---|---|---|
Market Cap | $1.31B | $29.63B |
Sector | Health | Industrials |
52-Week High | $11.19 | $73.82 |
52-Week Low | $6.22 | $53.24 |
Enterprise Value | $889.30M | $26.61B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
RYAAY trades at $60.63, up 1.88% today, but faces a bearish technical signal with support at $58. Fundamentally, it shows strong profitability with a 12.13% net margin and a reasonable P/E of 14.37. Recent Q1 2026 earnings beat expectations despite a 34% profit decline due to lower fares and higher fuel costs (Reuters, 2026-07-20). The company maintains a robust balance sheet with $3.96B in cash and announced a strategic AI partnership with Google Cloud to enhance operations.
The outlook is mixed; analyst consensus is bullish (62.5% buy ratings), citing long-term advantages from industry consolidation and a strong financial position. However, near-term risks include volatile fuel prices, competitive fare pressures, and geopolitical tensions affecting travel demand. The stock presents a value opportunity for patient investors, but requires monitoring of operational execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
